Knee Osteoarthritis (OA)
-
Regulatory
Lipogems Announces Last Patient Enrolled in the U.S. FDA IDE Arise Study for the Treatment of Knee Osteoarthritis
Orthopaedic surgeon, Dr. Cristin Mathew, enrolls a patient in the Lipogems ARISE US FDA IDE Knee OA Study ATLANTA, April 10,…
Read More » -
Regulatory
Lipogems Announces First Patient Enrolled in the Second U.S. FDA IDE Study for the Treatment of Knee Osteoarthritis
Orthopaedic surgeon, Dr. Yogesh Mittal, enrolls the first patient in the ARISE 2 Study for Knee Osteoarthritis ATLANTA, April 8, 2024 /PRNewswire/…
Read More » -
Financial
Lipogems Raises €12.5M ($13.2M) to Accelerate the Expansion in Knee Osteoarthritis
ATLANTA, Dec. 26, 2022 /PRNewswire/ — Lipogems, a clinical stage- global medical technology company that utilizes autologous adipose tissue for therapeutic use in…
Read More » -
OSN Premium
Minimum Clinically Important Difference in Knee OA: A Deep Dive
by Elizabeth Hofheinz, M.P.H., M.Ed., August 30, 2019 You might say the Minimum Clinically Important Difference (MCID) is a way…
Read More » -
Sports Medicine
Breg Introduces New Osteoarthritis Knee Brace
CARLSBAD, Calif., Feb. 21, 2019 /PRNewswire/ — Breg, Inc., a premier provider of sports medicine products and services,has launched their next generation unloader…
Read More »